naltrexone Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
opioid receptor antagonists/agonists related to normorphine 1765 16590-41-3

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • naltrexone
  • cyclopropylmethylnoroxymorphone
  • naltrel
  • naltrexone hydrochloride
  • naltrexone hydrochloride dihydrate
  • naltrexone HCl
Derivative of noroxymorphone that is the N-cyclopropylmethyl congener of NALOXONE. It is a narcotic antagonist that is effective orally, longer lasting and more potent than naloxone, and has been proposed for the treatment of heroin addiction. The FDA has approved naltrexone for the treatment of alcohol dependence.
  • Molecular weight: 341.41
  • Formula: C20H23NO4
  • CLOGP: 0.36
  • LIPINSKI: 0
  • HAC: 5
  • HDO: 2
  • TPSA: 70
  • ALOGS: -2.05
  • ROTB: 2

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
50 mg O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 100 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 1 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.44 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 22 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 7.60 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 57 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.79 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 1.90 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Nov. 20, 1984 FDA TEVA WOMENS

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Injection site reaction 2995.34 20.25 1033 20310 46816 46617903
Alcoholism 2249.82 20.25 442 20901 1776 46662943
Injection site mass 2241.33 20.25 632 20711 14408 46650311
Injection site pain 1101.18 20.25 655 20688 106497 46558222
Injection site induration 821.55 20.25 253 21090 7826 46656893
Drug dependence 507.01 20.25 225 21118 19676 46645043
Therapeutic response shortened 437.53 20.25 141 21202 5058 46659661
Feeling abnormal 323.44 20.25 339 21004 124721 46539998
Product administered at inappropriate site 230.96 20.25 72 21271 2311 46662408
Withdrawal syndrome 230.96 20.25 128 21215 18006 46646713
Inappropriate schedule of product administration 207.88 20.25 198 21145 64815 46599904
Injection site abscess 190.01 20.25 51 21292 948 46663771
Injection site swelling 185.40 20.25 151 21192 40176 46624543
Nausea 163.90 20.25 682 20661 686772 45977947
Drug use disorder 143.16 20.25 52 21291 2683 46662036
Anxiety 120.23 20.25 260 21083 181697 46483022
Injection site warmth 117.23 20.25 75 21268 13697 46651022
Insomnia 111.60 20.25 238 21105 164686 46500033
Product dose omission issue 106.97 20.25 237 21106 168283 46496436
Needle issue 105.43 20.25 52 21291 5752 46658967
Drug screen positive 102.21 20.25 45 21298 3846 46660873
Injection site nodule 98.40 20.25 42 21301 3329 46661390
Inadequate analgesia 95.24 20.25 39 21304 2785 46661934
Lack of injection site rotation 94.35 20.25 21 21322 169 46664550
Alcohol use 93.68 20.25 37 21306 2405 46662314
Substance abuse 89.86 20.25 42 21301 4125 46660594
Tremor 87.70 20.25 175 21168 115464 46549255
Headache 79.13 20.25 428 20915 477924 46186795
Product administration error 78.61 20.25 68 21275 19613 46645106
Pneumonia 78.61 20.25 37 21306 376283 46288436
Acute kidney injury 74.27 20.25 10 21333 235845 46428874
Depression 73.82 20.25 207 21136 169897 46494822
Euphoric mood 67.99 20.25 35 21308 4237 46660482
Alcohol poisoning 65.34 20.25 28 21315 2240 46662479
Lack of administration site rotation 64.29 20.25 10 21333 3 46664716
Dizziness 64.06 20.25 316 21027 340098 46324621
Injection site pruritus 62.88 20.25 84 21259 39659 46625060
Injection site discomfort 62.15 20.25 31 21312 3511 46661208
Injection site erythema 61.69 20.25 117 21226 74310 46590409
Anaemia 60.09 20.25 21 21322 255758 46408961
Rheumatoid arthritis 59.46 20.25 18 21325 240197 46424522
Necrosis ischaemic 59.33 20.25 20 21323 825 46663894
Injection site cyst 58.37 20.25 11 21332 33 46664686
Drug titration error 57.53 20.25 18 21325 584 46664135
Injection site cellulitis 56.71 20.25 21 21322 1144 46663575
Dependence 56.16 20.25 24 21319 1907 46662812
Body tinea 53.53 20.25 19 21324 916 46663803
Irritability 50.17 20.25 64 21279 28882 46635837
Imprisonment 46.21 20.25 12 21331 195 46664524
Pneumonia streptococcal 45.80 20.25 20 21323 1675 46663044
Inhibitory drug interaction 45.79 20.25 21 21322 1974 46662745
Hypotension 45.29 20.25 25 21318 232564 46432155
Magnesium deficiency 45.23 20.25 14 21329 438 46664281
Pregnancy 43.91 20.25 58 21285 27079 46637640
Injection site infection 43.77 20.25 19 21324 1568 46663151
Beta haemolytic streptococcal infection 43.72 20.25 20 21323 1869 46662850
Neutropenia 42.90 20.25 7 21336 143197 46521522
Injection site bruising 41.29 20.25 65 21278 35571 46629148
Thrombocytopenia 40.69 20.25 5 21338 126576 46538143
Panic attack 40.31 20.25 48 21295 20194 46644525
Dyspnoea 39.24 20.25 114 21229 515434 46149285
Alcohol abuse 38.08 20.25 19 21324 2153 46662566
Infection susceptibility increased 38.02 20.25 19 21324 2160 46662559
Feeling drunk 37.68 20.25 23 21320 3864 46660855
Crying 37.04 20.25 47 21296 21094 46643625
Poor quality sleep 36.87 20.25 40 21303 15213 46649506
Fatigue 36.84 20.25 432 20911 608265 46056454
Alcohol withdrawal syndrome 36.78 20.25 14 21329 823 46663896
Impaired work ability 35.67 20.25 36 21307 12600 46652119
Surgery 35.44 20.25 54 21289 28731 46635988
Food craving 35.34 20.25 15 21328 1172 46663547
Haemoglobin decreased 35.03 20.25 8 21335 128941 46535778
Apathy 35.02 20.25 28 21315 7240 46657479
Wrong technique in product usage process 34.94 20.25 77 21266 54345 46610374
Platelet count decreased 34.60 20.25 3 21340 100021 46564698
Pyrexia 34.57 20.25 67 21276 348735 46315984
Death 34.53 20.25 63 21280 335485 46329234
Oedema peripheral 34.35 20.25 15 21328 159691 46505028
Detoxification 34.27 20.25 6 21337 10 46664709
Sepsis 33.97 20.25 10 21333 136004 46528715
Impaired quality of life 33.54 20.25 20 21323 3222 46661497
Suicidal ideation 33.10 20.25 77 21266 56305 46608414
Illness 33 20.25 34 21309 12190 46652529
Feeling jittery 32.24 20.25 32 21311 10976 46653743
General physical health deterioration 31.81 20.25 7 21336 115762 46548957
Atrial fibrillation 31.16 20.25 5 21338 103585 46561134
Malabsorption from injection site 30.91 20.25 6 21337 22 46664697
Cough 30.75 20.25 36 21307 230213 46434506
Hospitalisation 30.28 20.25 80 21263 63305 46601414
Injection site necrosis 30.21 20.25 14 21329 1348 46663371
Drug withdrawal syndrome 29.06 20.25 48 21295 27336 46637383
Renal failure 29.01 20.25 8 21335 113586 46551133
Fall 28.61 20.25 68 21275 329029 46335690
Glucose tolerance impaired 28.51 20.25 21 21322 4810 46659909
Disease progression 28.39 20.25 4 21339 91296 46573423
Cardiac arrest 28.02 20.25 4 21339 90395 46574324
Mood altered 27.82 20.25 32 21311 12975 46651744
Toothache 27.67 20.25 36 21307 16556 46648163
Malaise 27.51 20.25 251 21092 330981 46333738
Pulmonary embolism 27.08 20.25 8 21335 108577 46556142
Condition aggravated 27.02 20.25 44 21299 245008 46419711
Somnolence 26.99 20.25 142 21201 156379 46508340
Cold sweat 26.97 20.25 29 21314 10916 46653803
Drug intolerance 26.91 20.25 17 21326 147032 46517687
Caffeine consumption 26.76 20.25 4 21339 0 46664719
Abnormal dreams 26.69 20.25 28 21315 10251 46654468
White blood cell count decreased 26.68 20.25 9 21334 112222 46552497
Hypersomnia 26.53 20.25 34 21309 15405 46649314
Feeling of despair 26.47 20.25 14 21329 1791 46662928
Restlessness 26.09 20.25 44 21299 25480 46639239
Restless legs syndrome 25.84 20.25 34 21309 15809 46648910
Aspartate aminotransferase increased 25.55 20.25 3 21340 78697 46586022
Adiposis dolorosa 25.35 20.25 8 21335 267 46664452
Migraine 25.34 20.25 80 21263 69946 46594773
Alanine aminotransferase increased 25.01 20.25 5 21338 88446 46576273
Urinary tract infection 24.79 20.25 39 21304 220227 46444492
Road traffic accident 24.43 20.25 41 21302 23650 46641069
Injection site irritation 23.88 20.25 18 21325 4269 46660450
Mass 23.80 20.25 28 21315 11625 46653094
Exposure during pregnancy 23.52 20.25 10 21333 108202 46556517
Hyponatraemia 22.61 20.25 9 21334 101323 46563396
Death of relative 22.47 20.25 7 21336 224 46664495
Blood creatinine increased 22.28 20.25 4 21339 76399 46588320
Product preparation issue 22.28 20.25 8 21335 399 46664320
Anger 21.79 20.25 27 21316 11825 46652894
Patient dissatisfaction with treatment 21.06 20.25 5 21338 55 46664664
Gastrointestinal haemorrhage 20.61 20.25 5 21338 77368 46587351
Blood glucose increased 20.51 20.25 4 21339 72009 46592710

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Injection site reaction 4568.28 26.50 1110 18104 9650 29923614
Injection site pain 2568.09 26.50 894 18320 29416 29903848
Alcoholism 2443.92 26.50 540 18674 2874 29930390
Injection site mass 1278.43 26.50 345 18869 4608 29928656
Drug dependence 880.91 26.50 374 18840 20921 29912343
Feeling abnormal 600.96 26.50 401 18813 56355 29876909
Therapeutic response shortened 598.49 26.50 178 19036 3422 29929842
Injection site induration 528.07 26.50 148 19066 2281 29930983
Withdrawal syndrome 340.53 26.50 159 19055 11091 29922173
Product administered at inappropriate site 311.95 26.50 90 19124 1545 29931719
Injection site swelling 303.12 26.50 136 19078 8644 29924620
Needle issue 284.46 26.50 103 19111 3729 29929535
Product dose omission issue 276.01 26.50 316 18898 91315 29841949
Insomnia 256.30 26.50 307 18907 93029 29840235
Drug use disorder 251.20 26.50 90 19124 3158 29930106
Inappropriate schedule of product administration 205.88 26.50 184 19030 39544 29893720
Alcohol use 178.57 26.50 73 19141 3682 29929582
Lack of injection site rotation 172.46 26.50 33 19181 69 29933195
Injection site discomfort 165.80 26.50 51 19163 1100 29932164
Depression 158.24 26.50 239 18975 90198 29843066
Drug screen positive 141.71 26.50 65 19149 4342 29928922
Anxiety 134.32 26.50 221 18993 89650 29843614
Pain 131.44 26.50 320 18894 172321 29760943
Acute kidney injury 126.94 26.50 14 19200 273828 29659436
Product administration error 117.63 26.50 87 19127 14290 29918974
Euphoric mood 115.56 26.50 56 19158 4234 29929030
Headache 111.12 26.50 311 18903 181995 29751269
Nausea 104.76 26.50 421 18793 296536 29636728
Dependence 98.66 26.50 35 19179 1191 29932073
Apathy 93.25 26.50 55 19159 6177 29927087
Drug withdrawal syndrome 93.22 26.50 87 19127 19722 29913542
Pneumonia 92.36 26.50 50 19164 334256 29599008
Malaise 92.16 26.50 275 18939 166687 29766577
Substance abuse 92.11 26.50 57 19157 6983 29926281
Irritability 89.30 26.50 91 19123 22959 29910305
Anaemia 88.23 26.50 14 19200 207978 29725286
Imprisonment 84.34 26.50 25 19189 473 29932791
Alcohol poisoning 80.41 26.50 42 19172 3722 29929542
Injection site abscess 79.70 26.50 26 19188 682 29932582
Yawning 73.16 26.50 23 19191 534 29932730
Feeling drunk 71.96 26.50 30 19184 1589 29931675
Injection site erythema 65.54 26.50 61 19153 13773 29919491
Emotional poverty 65.35 26.50 19 19195 335 29932929
Decreased appetite 63.72 26.50 226 18988 149684 29783580
Inadequate analgesia 62.99 26.50 32 19182 2676 29930588
Fatigue 62.24 26.50 384 18830 320289 29612975
Tremor 60.66 26.50 143 19071 75220 29858044
Injection site warmth 59.25 26.50 27 19187 1775 29931489
Injection site bruising 59.09 26.50 44 19170 7294 29925970
Injection site nerve damage 58.23 26.50 10 19204 7 29933257
Toxicity to various agents 57.42 26.50 21 19193 177162 29756102
Lack of administration site rotation 57.17 26.50 9 19205 0 29933264
Renal failure 56.19 26.50 8 19206 128958 29804306
Injection site nodule 54.83 26.50 24 19190 1434 29931830
Road traffic accident 54.78 26.50 61 19153 17010 29916254
Sepsis 51.56 26.50 15 19199 146380 29786884
Hypotension 51.00 26.50 33 19181 200532 29732732
Feeling of despair 50.64 26.50 20 19194 920 29932344
Depressed mood 49.81 26.50 58 19156 16971 29916293
Substance use disorder 49.18 26.50 12 19202 103 29933161
Atrial fibrillation 48.78 26.50 6 19208 108118 29825146
Thrombocytopenia 48.33 26.50 14 19200 137030 29796234
Neutropenia 47.46 26.50 12 19202 128528 29804736
Dyspnoea 46.33 26.50 90 19124 333205 29600059
Alcohol withdrawal syndrome 46.07 26.50 22 19192 1609 29931655
Haemoglobin decreased 45.44 26.50 9 19205 114089 29819175
Platelet count decreased 45.25 26.50 7 19207 106122 29827142
Pyrexia 43.13 26.50 77 19137 294412 29638852
Respiratory failure 42.10 26.50 7 19207 100635 29832629
Mood altered 40.27 26.50 37 19177 8213 29925051
Cardiac failure congestive 39.79 26.50 4 19210 84403 29848861
Disease progression 39.79 26.50 3 19211 79871 29853393
Anger 39.63 26.50 42 19172 11078 29922186
Injection site pruritus 39.46 26.50 31 19183 5561 29927703
Overdose 39.11 26.50 131 19083 84206 29849058
Blood creatinine increased 39.01 26.50 6 19208 91369 29841895
Condition aggravated 38.83 26.50 20 19194 137846 29795418
Toothache 38.41 26.50 31 19183 5780 29927484
Restlessness 38.36 26.50 59 19155 22540 29910724
Abdominal pain upper 37.21 26.50 106 19108 62445 29870819
Oedema peripheral 36.95 26.50 11 19203 105821 29827443
Cardiac failure 36.72 26.50 5 19209 83413 29849851
Substance use 36.57 26.50 13 19201 445 29932819
Sciatic nerve injury 35.21 26.50 9 19205 95 29933169
Myocardial infarction 34.23 26.50 19 19195 125606 29807658
Hypersomnia 33.86 26.50 39 19175 11277 29921987
General physical health deterioration 33.80 26.50 11 19203 99933 29833331
Gait disturbance 33.64 26.50 115 19099 74662 29858602
Energy increased 32.39 26.50 16 19198 1260 29932004
Injection site infection 31.88 26.50 14 19200 843 29932421
Hangover 31.85 26.50 15 19199 1063 29932201
Injection site inflammation 31.78 26.50 13 19201 656 29932608
Panic attack 31.31 26.50 33 19181 8648 29924616
Mood swings 31.15 26.50 31 19183 7595 29925669
Feeling jittery 30.81 26.50 23 19191 3825 29929439
White blood cell count decreased 30.65 26.50 8 19206 83939 29849325
Death of relative 30.33 26.50 6 19208 16 29933248
Thinking abnormal 30.26 26.50 26 19188 5285 29927979
Alcohol abuse 30.08 26.50 26 19188 5327 29927937
Hyperhidrosis 30.02 26.50 103 19111 66987 29866277
Muscle spasms 28.53 26.50 99 19115 64739 29868525
Migraine 28.28 26.50 38 19176 12836 29920428
Injection site cellulitis 28.21 26.50 11 19203 489 29932775
Product preparation error 28.02 26.50 16 19198 1690 29931574
Sluggishness 27.92 26.50 20 19194 3123 29930141
Chromaturia 27.57 26.50 39 19175 13826 29919438
Emotional disorder 27.13 26.50 24 19190 5070 29928194
Wrong technique in product usage process 27.10 26.50 61 19153 31094 29902170
Urinary tract infection 26.93 26.50 7 19207 73652 29859612
Opiates positive 26.86 26.50 9 19205 257 29933007

Pharmacologic Action:

SourceCodeDescription
ATC A08AA62 ALIMENTARY TRACT AND METABOLISM
ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS
ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS
Centrally acting antiobesity products
ATC N02AA56 NERVOUS SYSTEM
ANALGESICS
OPIOIDS
Natural opium alkaloids
ATC N07BB04 NERVOUS SYSTEM
OTHER NERVOUS SYSTEM DRUGS
DRUGS USED IN ADDICTIVE DISORDERS
Drugs used in alcohol dependence
FDA MoA N0000000154 Opioid Antagonists
FDA EPC N0000175691 Opioid Antagonist
MeSH PA D000427 Alcohol Deterrents
MeSH PA D002491 Central Nervous System Agents
MeSH PA D009292 Narcotic Antagonists
MeSH PA D018373 Peripheral Nervous System Agents
MeSH PA D018689 Sensory System Agents
CHEBI has role CHEBI:35488 cns depressants
CHEBI has role CHEBI:35703 xenobiotic
CHEBI has role CHEBI:50137 mu-opioid receptor antagonists
CHEBI has role CHEBI:78298 environmental contaminants
CHEBI has role CHEBI:90755 antidote to opioid overdose

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Alcoholism indication 7200002
Severe pain indication 76948002
Chronic pain indication 82423001
Obesity indication 414916001 DOID:9970
Prevention of opioid abuse indication 426928008
Therapeutic opioid induced constipation indication 136801000119102
Severe Pain with Opioid Tolerance indication
Chronic Pain with Opioid Tolerance indication
Neuropathic pain off-label use 247398009
Suicidal thoughts contraindication 6471006
Alcohol withdrawal delirium contraindication 8635005
Chronic obstructive lung disease contraindication 13645005 DOID:3083
Chronic disease of respiratory system contraindication 17097001
Alcohol intoxication contraindication 25702006
Shock contraindication 27942005
Hypercapnia contraindication 29596007
Depressive disorder contraindication 35489007
Acute hepatitis contraindication 37871000
Disorder of gallbladder contraindication 39621005 DOID:0060262
Gastrointestinal ulcer contraindication 40845000
Hypothyroidism contraindication 40930008 DOID:1459
Low blood pressure contraindication 45007003
Gastrointestinal perforation contraindication 51875005
Paralytic ileus contraindication 55525008 DOID:8442
Acute nephropathy contraindication 58574008
Hepatic failure contraindication 59927004
Substance abuse contraindication 66214007
Benign intracranial hypertension contraindication 68267002 DOID:11459
Opioid dependence contraindication 75544000 DOID:2559
Urethral stricture contraindication 76618002
Decreased respiratory function contraindication 80954004
Injury of head contraindication 82271004
Cor pulmonale contraindication 83291003 DOID:8515
Opioid withdrawal contraindication 87132004
Disorder of biliary tract contraindication 105997008 DOID:9741
Gastrointestinal obstruction contraindication 126765001
Seizure disorder contraindication 128613002
Drug-induced psychosis contraindication 191483003 DOID:1742
Acute hepatic failure contraindication 197270009
Acute pancreatitis contraindication 197456007 DOID:2913
Impaired renal function disorder contraindication 197663003
Disease of liver contraindication 235856003 DOID:409
Chronic diarrhea contraindication 236071009
Benign prostatic hyperplasia contraindication 266569009
Primary malignant neoplasm of gastrointestinal tract contraindication 363745004
Macrocolon contraindication 367495003
Eosinophilic asthma contraindication 367542003 DOID:9498
Primary adrenocortical insufficiency contraindication 373662000
Severe diarrhea contraindication 409587002
Central nervous system depression contraindication 418072004
Acute exacerbation of asthma contraindication 708038006
Increased Creatine Phosphokinase contraindication
Pain in Opioid Naive Patients contraindication
Opioid Use Within Last 4 Hours in Narcotic-Dependent Patient contraindication

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 9.31 acidic
pKa2 7.66 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Mu-type opioid receptor GPCR ANTAGONIST Ki 9.38 WOMBAT-PK CHEMBL
Kappa-type opioid receptor GPCR ANTAGONIST Ki 8.93 WOMBAT-PK CHEMBL
Delta-type opioid receptor GPCR ANTAGONIST Ki 7.99 WOMBAT-PK CHEMBL
Neuronal acetylcholine receptor subunit alpha-7 Ion channel IC50 4.60 CHEMBL
Cytochrome P450 2D6 Enzyme IC50 6 DRUG MATRIX
Kappa-type opioid receptor GPCR Ki 8.84 CHEMBL
Neuronal acetylcholine receptor subunit alpha-4 Ion channel IC50 4.51 CHEMBL
Delta-type opioid receptor GPCR Ki 7.91 CHEMBL
Mu-type opioid receptor GPCR Ki 9.77 CHEMBL
Opioid receptor GPCR Ki 9.26 CHEMBL
Opioid receptors; mu and delta GPCR Ki 9.06 CHEMBL
Mu-type opioid receptor GPCR Ki 9.58 CHEMBL
Kappa-type opioid receptor GPCR Ki 8.97 CHEMBL
Delta-type opioid receptor GPCR Ki 8.32 CHEMBL
Mu-type opioid receptor GPCR Ki 9.34 CHEMBL
Kappa-type opioid receptor GPCR Ki 9.51 CHEMBL

External reference:

IDSource
4019853 VUID
N0000147939 NUI
D02095 KEGG_DRUG
16676-29-2 SECONDARY_CAS_RN
4018545 VANDF
4019853 VANDF
C0027360 UMLSCUI
CHEBI:7465 CHEBI
CHEMBL19019 ChEMBL_ID
CHEMBL1201149 ChEMBL_ID
D009271 MESH_DESCRIPTOR_UI
DB00704 DRUGBANK_ID
1639 IUPHAR_LIGAND_ID
3368 INN_ID
5S6W795CQM UNII
5485201 PUBCHEM_CID
105069 RXNORM
11621 MMSL
20600 MMSL
5151 MMSL
d01406 MMSL
001615 NDDF
004662 NDDF
373546002 SNOMEDCT_US
64191009 SNOMEDCT_US
87617007 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
NULLLTREXONE HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 0406-1170 TABLET, FILM COATED 50 mg ORAL ANDA 15 sections
NULLLTREXONE HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 0904-7036 TABLET, FILM COATED 50 mg ORAL ANDA 22 sections
EMBEDA HUMAN PRESCRIPTION DRUG LABEL 2 16590-897 CAPSULE, EXTENDED RELEASE 0.80 mg ORAL NDA 14 sections
Naltrexone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 16729-081 TABLET, FILM COATED 50 mg ORAL ANDA 23 sections
Naltrexone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 42291-632 TABLET, FILM COATED 50 mg ORAL ANDA 25 sections
ContraveExtended-Release HUMAN PRESCRIPTION DRUG LABEL 2 43063-772 TABLET, EXTENDED RELEASE 8 mg ORAL NDA 30 sections
NULLLTREXONE HYDROCHLORIDE Human Prescription Drug Label 1 47335-326 TABLET, FILM COATED 50 mg ORAL ANDA 22 sections
Naltrexone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 50090-2866 TABLET, FILM COATED 50 mg ORAL ANDA 27 sections
ContraveExtended-Release HUMAN PRESCRIPTION DRUG LABEL 2 50090-2945 TABLET, EXTENDED RELEASE 8 mg ORAL NDA 30 sections
NULLLTREXONE HYDROCHLORIDE Human Prescription Drug Label 1 50090-3929 TABLET, FILM COATED 50 mg ORAL ANDA 23 sections
Naltrexone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 50090-4925 TABLET, FILM COATED 50 mg ORAL ANDA 23 sections
Naltrexone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 51224-206 TABLET, FILM COATED 50 mg ORAL ANDA 28 sections
ContraveExtended-Release HUMAN PRESCRIPTION DRUG LABEL 2 51267-890 TABLET, EXTENDED RELEASE 8 mg ORAL NDA 31 sections
Naltrexone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 53217-261 TABLET, FILM COATED 50 mg ORAL ANDA 25 sections
Naltrexone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 54868-5574 TABLET, FILM COATED 50 mg ORAL ANDA 26 sections
Addex-1000 HUMAN PRESCRIPTION DRUG LABEL 1 57377-010 PELLET, IMPLANTABLE 1000 mg SUBCUTANEOUS Export only 4 sections
Naltrexone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 63629-1046 TABLET, FILM COATED 50 mg ORAL ANDA 27 sections
Naltrexone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 63629-1047 TABLET, FILM COATED 50 mg ORAL ANDA 27 sections
NULLLTREXONE HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 68084-291 TABLET, FILM COATED 50 mg ORAL ANDA 16 sections
Naltrexone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 68094-853 TABLET, FILM COATED 50 mg ORAL ANDA 26 sections
Naltrexone HUMAN PRESCRIPTION DRUG LABEL 2 69364-3143 IMPLANT 200 mg SUBCUTANEOUS Unapproved drug other 25 sections
Naltrexone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 70518-1146 TABLET, FILM COATED 50 mg ORAL ANDA 23 sections
NULLLTREXONE HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 70518-2718 TABLET, FILM COATED 50 mg ORAL ANDA 22 sections
Naltrexone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 71335-0014 TABLET, FILM COATED 50 mg ORAL ANDA 23 sections
NULLLTREXONE HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 71335-1480 TABLET, FILM COATED 50 mg ORAL ANDA 15 sections
NULLLTREXONE HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 76519-1160 TABLET, FILM COATED 50 mg ORAL ANDA 13 sections